VIDEO: TearCare system shows improved tear break up time in DED, MGD vs. 'standard of care'
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Brandon D. Ayres, MD, discusses data from the SAHARA trial, which evaluated patients with dry eye disease and meibomian gland dysfunction.
The randomized controlled study compared the TearCare system with 6 months of twice-daily Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan). The trial’s primary endpoints included tear break up time and the ocular surface disease index or patient reported outcomes of their dry eye symptoms.
At 6 months, patients showed a better tear break up time using the TearCare system at all time points.
“To my knowledge, this is one of the largest studies comparing an interventional lid margin procedure with the standard of care, which would be topical cyclosporine 0.05%, in this case branded Restasis,” he said. “It really shows us that we can treat patients nicely and effectively using a lid margin procedure as opposed to prescription medications.”
Collapse
Healio Interviews
Click Here to Manage Email Alerts